Neumora discontinues navacaprant after Phase 3 failures in depression

Neumora's Phase 3 KOASTAL-2 and -3 studies of navacaprant failed to meet primary endpoints for major depressive disorder, prompting the company to halt development. The company is implementing a 35% workforce reduction and refocusing on three pipeline programs with cash runway through Q3 2027.